HomeCompareARNA vs SPHD

ARNA vs SPHD: Dividend Comparison 2026

ARNA yields 2.00% · SPHD yields 4.33%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SPHD wins by $3.9K in total portfolio value
10 years
ARNA
ARNA
● Live price
2.00%
Share price
$99.99
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.6K
Annual income
$227.64
Full ARNA calculator →
SPHD
SPHD
● Live price
4.33%
Share price
$49.34
Annual div
$2.14
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.5K
Annual income
$571.32
Full SPHD calculator →

Portfolio growth — ARNA vs SPHD

📍 SPHD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodARNASPHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ARNA + SPHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ARNA pays
SPHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ARNA
Annual income on $10K today (after 15% tax)
$170.02/yr
After 10yr DRIP, annual income (after tax)
$193.49/yr
SPHD
Annual income on $10K today (after 15% tax)
$367.92/yr
After 10yr DRIP, annual income (after tax)
$485.62/yr
At 15% tax rate, SPHD beats the other by $292.13/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ARNA + SPHD for your $10,000?

ARNA: 50%SPHD: 50%
100% SPHD50/50100% ARNA
Portfolio after 10yr
$24.6K
Annual income
$399.48/yr
Blended yield
1.63%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARNA right now

ARNA
Analyst Ratings
14
Buy
9
Hold
Consensus: Buy
Price Target
$94.00
-6.0% upside vs current
Range: $90.00 — $100.00
SPHD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ARNA buys
0
SPHD buys
0
No recent congressional trades found for ARNA or SPHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricARNASPHD
Forward yield2.00%4.33%
Annual dividend / share$2.00$2.14
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$22.6K$26.5K
Annual income after 10y$227.64$571.32
Total dividends collected$2.1K$5.1K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: ARNA vs SPHD ($10,000, DRIP)

YearARNA PortfolioARNA Income/yrSPHD PortfolioSPHD Income/yrGap
1← crossover$10,900$200.02$11,133$432.85$233.00SPHD
2$11,867$203.76$12,363$450.36$496.00SPHD
3$12,905$207.32$13,695$467.39$790.00SPHD
4$14,019$210.70$15,138$483.90$1.1KSPHD
5$15,214$213.92$16,697$499.88$1.5KSPHD
6$16,496$216.97$18,382$515.31$1.9KSPHD
7$17,871$219.86$20,198$530.17$2.3KSPHD
8$19,344$222.60$22,157$544.46$2.8KSPHD
9$20,923$225.19$24,266$558.18$3.3KSPHD
10$22,616$227.64$26,536$571.32$3.9KSPHD

ARNA vs SPHD: Complete Analysis 2026

ARNAStock

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.

Full ARNA Calculator →

SPHDETF

The Invesco S&P 500 High Dividend Low Volatility ETF (Fund) is based on the S&P 500 Low Volatility High Dividend Index (Index). The Fund will invest at least 90% of its total assets in common stocks that comprise the Index. Standard & Poor's compiles, maintains and calculates the Index, which is composed of 50 securities traded on the S&P 500 Index that historically have provided high dividend yields and low volatility. The Fund and the Index are rebalanced and reconstituted semi-annually, in January and July.

Full SPHD Calculator →
📬

Get this ARNA vs SPHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ARNA vs SCHDARNA vs JEPIARNA vs OARNA vs KOARNA vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.